India’s Lupin Gets FDA Warning for Two Pharma Facilities

Indian drugmaker Lupin Ltd. received a warning letter from FDA for two of its manufacturing facilities and said new product approvals may be delayed due to the letter.

The Food and Drug Administration issued the warning letter for Lupin’s Goa and Indore manufacturing sites, the company said in a Nov. 7 letter to the National Stock Exchange of India. Lupin said while the warning letter will likely delay new product approvals from these facilities, it won’t disrupt existing product supplies from either location.

The FDA has been increasing its focus on Indian drug manufacturers in recent years. In ...